A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by:
Cancer Prevention Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT01245816
First received: November 19, 2010
Last updated: May 27, 2011
Last verified: May 2011

November 19, 2010
May 27, 2011
March 2011
May 2013   (final data collection date for primary outcome measure)
Efficacy of Eflornithine plus Sulindac compared to Eflornithine alone and Sulindac alone determined by change in the number of polyps 2 mm or greater in a defined focal area of the rectum or pouch at baseline and after completion of the study treatment. [ Time Frame: 6 months from the start of treatment. ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01245816 on ClinicalTrials.gov Archive Site
  • Change in number of polyps 2 mm or greater in the distal 10 cm of rectum or pouch. [ Time Frame: 6 months from the start of treatment. ] [ Designated as safety issue: No ]
  • Qualitative change in overall colon/rectum/pouch polyp burden (number and size). [ Time Frame: 6 months from the start of treatment. ] [ Designated as safety issue: No ]
  • Presence of high grade dysplasia or villous adenoma in any polyp resected. [ Time Frame: 6 months from the start of treatment. ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)
A Randomized Phase III Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)

The purpose of this phase III study is to evaluate the safety and efficacy of the combination of eflornithine and sulindac compared to single agent sulindac or eflornithine in reducing the number of polyps in patients with familial adenomatous polyposis (FAP).

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Familial Adenomatous Polyposis
  • Drug: Eflornithine plus Sulindac
    Eflornithine, 250 mg tablet, two tablets (500 mg) orally once a day; Sulindac, 150 mg tablet, one tablet orally once a day
    Other Name: DFMO
  • Drug: Eflornithine plus Placebo
    Eflornithine, 250 mg tablet, two tablets (500 mg) orally once a day; Placebo, one tablet orally once a day
    Other Name: DFMO
  • Drug: Sulindac plus Placebo
    Sulindac, 150 mg tablet, one tablet orally once a day; Placebo, two tablets orally once a day
  • Experimental: Eflornithine plus Sulindac
    Eflornithine 500 mg and Sulindac 150 mg
    Intervention: Drug: Eflornithine plus Sulindac
  • Active Comparator: Elfornithine plus Placebo
    Eflornithine 500 mg and Placebo
    Intervention: Drug: Eflornithine plus Placebo
  • Active Comparator: Sulindac plus Placebo
    Sulindac 150 mg and Placebo
    Intervention: Drug: Sulindac plus Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
140
June 2013
May 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of phenotypic Familial Adenomatous Polyposis (FAP) of the colorectum based on meeting the criteria in one of two groups: Group 1-Greater than 100 adenomatous colorectal polyps prior to age 40. Group 2-Greater than 10 adenomatous polyps and age <40 or greater than 25 polyps and age >40; combined with a dominant family history or genotype: More than 100 polyps in a first-degree relative; More than 25 polyps in 2 relatives in 2 generations, including a first-degree family member; Genetic diagnosis in a relative; Genetic diagnosis by in vitro synthesized truncated protein or similar assay.
  • No colorectal surgery or prior colon surgery for polyposis at least 1 year prior (total abdominal colectomy with ileal-rectal anastomosis, or total proctocolectomy with ilea pouch-anal reconstruction.
  • Baseline endoscopy

    1. If no prior colorectal surgery, at least 3 polyps in a cluster each ≥ 2 mm in diameter; or
    2. If rectum is in situ and to be assessed, baseline rectal segment endoscopy documenting 3 or more rectal polyps each at least 2 mm in diameter in a defined cluster and/or at least 6 polyps, ≥ 2 mm in diameter, in the distal 10 cm of rectum
    3. If ileal pouch neo-rectum is in place, 3 or more pouch polyps in a cluster ≥ 2 mm in diameter, or at least 6 polyps, ≥ 2 mm in diameter, in the distal 10 cm of pouch.
    4. Clinical/pathological grading of duodenal polyps will utilize the Spigelman Classification.
  • Hematopoietic: no significant hematologic dysfunction; WBC ≥3,000/mm3; platelet count ≥100,000/mm3; hemoglobin ≥10g/dL; no known or prior clinical coagulopathy.
  • Hepatic: bilirubin ≤ 1.5 times ULN; AST and ALT ≤ 1.5 times ULN; Alkaline phosphatase ≤ 1.5 times ULN.
  • Renal: No significant renal dysfunction; creatinine ≤ 1.5 times ULN.
  • Hearing: no clinically significant hearing loss that affects everyday life.
  • Not pregnant or nursing.
  • Negative serum pregnancy test if female of child-bearing potential.
  • Absence of gross blood in stool.
  • Fertile patients must use effective contraception.
  • Stool occult blood either negative or minimal (1+).
  • No prior hypersensitivity to cyclooxygenase-2 inhibitors, sulfonamides, NSAIDs, or salicylates; no NSAID associated symptoms of gastritis.
  • No discrete gastric or duodenal ulcer greater than 5 mm within the past year except Helicobacter pylori-related peptic ulcer disease treated successfully with antibiotics (as documented by an endoscopy.
  • No invasive malignancy within the past 5 years except stage I or II colon or rectal cancer or resected nonmelanomatous skin cancer.
  • No other significant medical or psychiatric problems that would preclude study participation.
  • No chronic adrenocorticosteroids.
  • No prior pelvic irradiation.
  • At least 3 months since prior investigational agents.
  • Patients may not be receiving or plan to receive corticosteroids.
  • Concomitant NSAID use outside this study may not exceed 4 days per month.
  • Use of 81 mg daily aspirin or 650 mg aspirin not more than once a week.
  • No concurrent warfarin, fluconazole, or lithium.
  • Must be willing and able to sign informed consent.

Exclusion Criteria:

  • High Risk for cardiovascular disease including clinical diabetes mellitus (Type I or II) requiring glycemic medications; Prior personal history of cardiovascular disease or, two or more of the following - hypertension or use of anti-hypertensive medications, hyperlipidemia or use of lipid-lowering medications or current smoker.
  • Hearing loss that affects everyday life and or for which a hearing aid is required.
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01245816
CPP FAP-301
Yes
Jeffrey Jacob, CEO, Cancer Prevention Pharmaceuticals, Inc.
Cancer Prevention Pharmaceuticals, Inc.
Not Provided
Study Director: Alfred M. Cohen, M.D. Cancer Prevention Pharmaceuticals, Inc.
Cancer Prevention Pharmaceuticals, Inc.
May 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP